Exchange Traded Concepts LLC Acquires 4,900 Shares of Kenvue Inc. $KVUE

Exchange Traded Concepts LLC boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 8.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 65,030 shares of the company’s stock after buying an additional 4,900 shares during the period. Exchange Traded Concepts LLC’s holdings in Kenvue were worth $1,361,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. lifted its stake in Kenvue by 4.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after purchasing an additional 4,034 shares during the last quarter. IFP Advisors Inc lifted its stake in Kenvue by 25.3% during the first quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock worth $369,000 after purchasing an additional 3,081 shares during the last quarter. Vident Advisory LLC bought a new stake in Kenvue during the first quarter worth about $520,000. AG2R LA Mondiale Gestion D Actifs bought a new stake in Kenvue during the first quarter worth about $1,725,000. Finally, Czech National Bank lifted its stake in Kenvue by 6.6% during the second quarter. Czech National Bank now owns 469,294 shares of the company’s stock worth $9,822,000 after purchasing an additional 28,930 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $16.96 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $32.55 billion, a P/E ratio of 22.92, a PEG ratio of 2.63 and a beta of 0.83. The stock’s 50 day moving average is $20.77 and its 200 day moving average is $22.00. Kenvue Inc. has a twelve month low of $16.89 and a twelve month high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 annualized dividend and a yield of 4.9%. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is 112.16%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Citigroup dropped their price target on Kenvue from $22.00 to $20.00 and set a “neutral” rating for the company in a research note on Tuesday, September 16th. Evercore ISI lowered their target price on Kenvue from $25.00 to $23.00 and set an “in-line” rating for the company in a research note on Monday, September 8th. Bank of America lowered their target price on Kenvue from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, July 15th. Royal Bank Of Canada lowered their target price on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday, August 8th. Finally, Zacks Research raised Kenvue to a “strong sell” rating in a research note on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Kenvue has an average rating of “Hold” and a consensus price target of $24.04.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.